---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-076382"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2024-06-28T23:59:59+00:00"
generated_at: "2026-06-01T00:33:27.591055+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "low"
source: SEC EDGAR
---

# Rezolute releases Phase 2 topline results for RZ402 in DME; no specifics in filing

## Summary
- Topline results from Phase 2 study of RZ402 in diabetic macular edema (DME) disclosed via website and SEC filing on June 28, 2024.
- Presentation originally provided during May 21, 2024 investor webcast; appendix added on June 28, 2024.
- Actual efficacy or safety data (e.g., p-values, responder rates) are not visible in the available 8-K or exhibit text.

## SEC filing metadata
- accession: 0001104659-24-076382
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2024-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465924076382/0001104659-24-076382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465924076382/tm2418270d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-076382
- JSON: https://secwatch.observer/filing/0001104659-24-076382.json
- Plain text: https://secwatch.observer/filing/0001104659-24-076382.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.